Recombinant Human Osteoprotegerin/TNFRSF11B protein (His Tag)

Species

Human

Purity

>90 %, SDS-PAGE

Tag

His Tag

Activity

not tested

Cat no : Eg0976



Product Information

Purity >90 %, SDS-PAGE
Endotoxin <0.1 EU/μg protein, LAL method
Activity
Not tested
Expression HEK293-derived Human Osteoprotegerin protein Glu22-Leu401 (Accession# O00300) with a His tag at the C-terminus.
GeneID 4982
Accession O00300
PredictedSize 44.4 kDa
SDS-PAGE 50-58 kDa, reducing (R) conditions
Formulation Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization.
Reconstitution Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water.
Storage Conditions
It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
  • Until expiry date, -20℃ to -80℃ as lyophilized proteins.
  • 3 months, -20℃ to -80℃ under sterile conditions after reconstitution.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature.

Background

Osteoprotegerin (OPG), also known as TNFRSF11B or OCIF, is a member of the tumor necrosis factor receptor super family (TNFRSF). It is a secreted glycoprotein that inhibits osteoclastogenesis and is involved in the regulation of bone density. Osteoprotegerin acts as decoy receptor for receptor activator of nuclear factor-kappa B ligand (RANKL) and neutralizes its function in osteoclastogenesis. Osteoprotegerin may function as a soluble decoy receptor for tumor necrosis factor (TNF)-related apoptosis inducing ligand (TRAIL) and inhibits TRAIL-induced apoptosis. TRAIL blocks osteoprotegerin mediated inhibition of osteoclastogenesis.

References:

1. Simonet WS. et al. (1997). Cell. 189(2):309-319. 2. Emery JG. et al. (1998). J Biol Chem. 273(23):14363-14367. 3. Yasuda H. et al. (1998). Proc Natl Acad Sci U S A. 95(7):3597-3602.